Also listed in trial records as 68Ga-PSMA-11, AAA517, Gallium Ga 68 Gozetotide
Source: ClinicalTrials.gov, U.S. National Library of Medicine — the 10 trials in our USA, Canada, Germany, France, Spain, China, Poland, Czechia, UK, Netherlands, Belgium, Sweden, Switzerland, Austria, South Korea, Singapore, Italy, Israel, Denmark, Mexico, Japan, Taiwan, Brazil and Australia registers that name Illuccix as an intervention.Synced 29 Sep 2026
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov registry records · Last verified · Editorial standards
At a glance
Illuccix is named as an intervention in 10 current clinical trials
in our USA, Canada, Germany, France, Spain, China, Poland, Czechia, UK, Netherlands, Belgium, Sweden, Switzerland, Austria, South Korea, Singapore, Italy, Israel, Denmark, Mexico, Japan, Taiwan, Brazil and Australia registers.
3 are recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is Novartis Pharmaceuticals (4). The most-studied condition is Prostatic Neoplasm.
No centralised EU authorisation (it may be authorised nationally)
First centralised authorisation
CACanada (Health Canada)
No new-drug Notice of Compliance since 1994
First new-drug NOC
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
Protections still running for marketed products containing Illuccix, as listed by the regulators. Expired patents and exclusivities, and discontinued products, are not shown.
US FDA Orange Book Gozellix, Illuccix, Locametz
3 listed patents; the last listed expires 9 Mar 2036 (US 12109277).
Latest patent on the drug substance itself: 15 Aug 2028 (US 11369590).
Patents and exclusivities above are pooled across 5 applications for this substance.
Reproduced from the FDA Orange Book and Purple Book (checked 28 Sep 2026) and the European Commission's Union Register of medicinal products (CC BY 4.0; the EU expiry date is calculated exactly as the Commission's register displays it). Listed patents and dates are as submitted to or published by the regulator and may not reflect litigation, invalidation, settlements, lapsed fees or later extensions. This is not legal advice or a freedom-to-operate opinion, and it does not say when a generic or biosimilar will launch.
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
10 current trials in our USA, Canada, Germany, France, Spain, China, Poland, Czechia, UK, Netherlands, Belgium, Sweden, Switzerland, Austria, South Korea, Singapore, Italy, Israel, Denmark, Mexico, Japan, Taiwan, Brazil and Australia registers name Illuccix (also registered as 68Ga-PSMA-11) as a drug or biological intervention, as of the registry sync on 29 September 2026. Completed and withdrawn studies are not counted.
Are Illuccix trials recruiting patients?
Yes. 3 of the 10 trials are recruiting: 1 with sites in USA, 2 with sites in China and 1 with sites in Australia. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Illuccix clinical trials?
Novartis Pharmaceuticals (4), First Affiliated Hospital of Fujian Medical University (2), Telix Pharmaceuticals (Innovations) Pty Limited (1) and Peking Union Medical College Hospital (1), among 6 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Illuccix works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Illuccix works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Illuccix (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 29 Sep 2026.
Please verify before you rely on this.
This page is general information for life-science and pharmaceutical professionals. It is
not medical advice, and it has not been reviewed by a clinician — our editorial
team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most
recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC)
and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not
automatically interchangeable, and approvals, brand names and indications differ between the US, the
EU/Ireland (EMA/HPRA) and other regions.
Spotted an error? Tell us — we correct promptly and log it.
We value your privacy
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.